Oruka Therapeutics (NASDAQ:ORKA) Shares Up 8.4% – Should You Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price shot up 8.4% on Tuesday. The stock traded as high as $112.16 and last traded at $113.3830. Approximately 1,215,407 shares were traded during trading, an increase of 13% from the average daily volume of 1,077,189 shares. The stock had previously closed at $104.56.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Mizuho set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 3rd. Wedbush restated an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Trading Up 6.9%

The company has a market capitalization of $7.40 billion, a PE ratio of -55.51 and a beta of -0.34. The business’s 50-day simple moving average is $88.48 and its 200-day simple moving average is $70.92.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). Sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the sale, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 179,950 shares of company stock valued at $16,492,680 over the last 90 days. Insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $474,916,000. Remedium Capital Partners LLC lifted its stake in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after purchasing an additional 13,247 shares during the period. Jupiter Topco LLC purchased a new stake in Oruka Therapeutics during the second quarter worth $130,968,000. Avidity Partners Management LP boosted its holdings in Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares in the last quarter. Finally, Voya Investment Management LLC boosted its holdings in Oruka Therapeutics by 2.9% during the third quarter. Voya Investment Management LLC now owns 412,814 shares of the company’s stock worth $34,383,000 after buying an additional 11,665 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.